MMV022224

MMV022224 (72 h) potently inhibits the growth of P. falciparum (3D7) asexual blood stage parasites with an EC₅₀ of 217 nM^[1].
MMV022224 potently inhibits P. falciparum asexual blood stage parasites with an EC₅₀ of 390 nM and liver stage parasites with an EC₅₀ of 800 nM^[1].
MMV022224 (0.01-100 μM; 30 min) binds with highest affinity to PfPK6 (IC₅₀ = 161 nM) among a cohort of essential P. falciparum kinases, including PfCLK3 and PfPI(3,4)K, and demonstrates low-affinity binding to additional parasite kinases^[1].
MMV022224 (10 μM; 30 min pre-incubation) directly interacts with PfPK6 and PfCLK3 in P. falciparum 3D7 asexual blood stage lysates^[1].
MMV022224 inhibits recombinant PfPK6 enzymatic activity with an IC₅₀ of 800 nM, confirming it acts as a PfPK6 inhibitor^[1].
MMV022224 does not increase susceptibility in PfPK6 knockdown P. falciparum, indicating PfPK6 inhibition is not the sole driver of the compound's antimalarial activity^[1].
MMV022224 (8 h) potently inhibits Plasmodium falciparum 3D7-A10 ring and trophozoite stages (but not schizonts) and induces a unique metabolomic profile marked by increased peptide levels, indicating disruption of downstream hemoglobin catabolism^[2].
MMV022224 (72h) exposure increases peptide levels in Plasmodium falciparum 3D7-MR4 trophozoites, indicating a unique mode of action targeting downstream hemoglobin catabolism^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.